The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy.

Wu J, Xiao D, Yu K, Shalamu K, He B, Zhang M

Acta biochimica et biophysica Sinica1 Feb 2023Cited by 26 (Europe PMC)

PMID36786072PMCIDPMC10157545DOI10.3724/abbs.2023006PepBankPUB-36786072

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. No result from this study comes from people.

01AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment reduced IL-1β mRNA in cardiomyocytes.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c lowered a heart-cell inflammation signal, IL-1β.
Peptide
MOTS-c
Outcome
DecreaseIL-1β mRNA in cardiomyocytes
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Our results demonstrate that MOTS-c treatment reduces the mRNA levels of inflammatory cytokines ( IL-1β, IL-4, IL-6, and TNFα) in cardiomyocytes
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607201
02AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment reduced IL-4 mRNA in cardiomyocytes.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c lowered a heart-cell immune signal, IL-4.
Peptide
MOTS-c
Outcome
DecreaseIL-4 mRNA in cardiomyocytes
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Our results demonstrate that MOTS-c treatment reduces the mRNA levels of inflammatory cytokines ( IL-1β, IL-4, IL-6, and TNFα) in cardiomyocytes
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607202
03AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment reduced IL-6 mRNA in cardiomyocytes.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c lowered a heart-cell inflammation signal, IL-6.
Peptide
MOTS-c
Outcome
DecreaseIL-6 mRNA in cardiomyocytes
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Our results demonstrate that MOTS-c treatment reduces the mRNA levels of inflammatory cytokines ( IL-1β, IL-4, IL-6, and TNFα) in cardiomyocytes
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607203
04AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment reduced TNFα mRNA in cardiomyocytes.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c lowered a heart-cell inflammation signal, TNFα.
Peptide
MOTS-c
Outcome
DecreaseTNFα mRNA in cardiomyocytes
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Our results demonstrate that MOTS-c treatment reduces the mRNA levels of inflammatory cytokines ( IL-1β, IL-4, IL-6, and TNFα) in cardiomyocytes
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607204
05AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment reduced circulating CK-MB.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c lowered the blood marker of heart injury CK-MB.
Peptide
MOTS-c
Outcome
DecreaseCirculating CK-MB
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
the levels of circulating myocardial injury markers, such as CK-MB and TnT
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607205
06AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment reduced circulating troponin T.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c lowered the blood marker of heart injury troponin T.
Peptide
MOTS-c
Outcome
DecreaseCirculating TnT
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
the levels of circulating myocardial injury markers, such as CK-MB and TnT
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607206
07AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment alleviated cardiomyocyte mitochondrial dysfunction.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c eased energy-unit problems in heart cells.
Peptide
MOTS-c
Outcome
DecreaseCardiomyocyte mitochondrial dysfunction
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
alleviates cardiomyocyte mitochondrial dysfunction and oxidative stress
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607207
08AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment alleviated cardiomyocyte oxidative stress.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c eased oxidative stress in heart cells.
Peptide
MOTS-c
Outcome
DecreaseCardiomyocyte oxidative stress
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
alleviates cardiomyocyte mitochondrial dysfunction and oxidative stress
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607208
09AnimalOther designEfficacy outcome
In an LPS model of septic cardiomyopathy, MOTS‑c treatment reduced cardiomyocyte apoptosis.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c reduced heart-cell death.
Peptide
MOTS-c
Outcome
DecreaseCardiomyocyte apoptosis
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
reduces cardiomyocyte apoptosis
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607209
10AnimalOther designMechanism
In an LPS model of septic cardiomyopathy, MOTS‑c treatment activated the AMPK signaling pathway.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c switched on the AMPK protective pathway.
Peptide
MOTS-c
Outcome
IncreaseAMPK pathway activation
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
activates cardioprotection-related signaling pathways, including AMPK, AKT, and ERK
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607210
11AnimalOther designMechanism
In an LPS model of septic cardiomyopathy, MOTS‑c treatment activated the AKT signaling pathway.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c switched on the AKT protective pathway.
Peptide
MOTS-c
Outcome
IncreaseAKT pathway activation
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
activates cardioprotection-related signaling pathways, including AMPK, AKT, and ERK
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607211
12AnimalOther designMechanism
In an LPS model of septic cardiomyopathy, MOTS‑c treatment activated the ERK signaling pathway.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c switched on the ERK protective pathway.
Peptide
MOTS-c
Outcome
IncreaseERK pathway activation
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
activates cardioprotection-related signaling pathways, including AMPK, AKT, and ERK
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607212
13AnimalOther designMechanism
In an LPS model of septic cardiomyopathy, MOTS‑c treatment inhibited the inflammation-related JNK pathway.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c switched off the JNK inflammation pathway.
Peptide
MOTS-c
Outcome
DecreaseJNK pathway inhibition
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
inhibits the inflammation-related signaling pathways JNK and STAT3
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607213
14AnimalOther designMechanism
In an LPS model of septic cardiomyopathy, MOTS‑c treatment inhibited the inflammation-related STAT3 pathway.
In plain wordsIn a lab model of sepsis heart damage, MOTS‑c switched off the STAT3 inflammation pathway.
Peptide
MOTS-c
Outcome
DecreaseSTAT3 pathway inhibition
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
inhibits the inflammation-related signaling pathways JNK and STAT3
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607214
15AnimalOther designMechanism
In an LPS model of septic cardiomyopathy, the AMPK inhibitor compound C abolished the positive effect of MOTS‑c.
In plain wordsIn a lab model of sepsis heart damage, blocking AMPK removed the benefit of MOTS‑c.
Peptide
MOTS-c
Outcome
No significant changeMOTS-c effect with AMPK inhibitor compound C
Study
n: not reported in source
LPS-induced septic cardiomyopathy
Comparator
Compound C (AMPK inhibitor)
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
However, treatment with the AMPK pathway inhibitor compound C (CC) abolishes the positive effect of MOTS-c on LPS stress.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we aim to explore the protective effect of MOTS-c on lipopolysaccharide (LPS)-induced septic cardiomyopathy.
Summary · context
LPS is used to establish a model of septic cardiomyopathy.
Report a problemFND-3678607215

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.